Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Global Bio-chem Technology Group Co Debt-to-EBITDA?
Global Bio-chem Technology Group CoGBCMY 33 Debt-to-EBITDA is 1.81 as of Dec. 2025. GuruFocus rates GBCMY with a GF Score™ of 33/100. The stock has 5 warning signs investors should review. Among 1,554 Consumer Packaged Goods companies, Global Bio-chem Technology Group Co ranks worse than 63.32% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
GBCMY'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -53.44 Med: -3.18 Max: 267.45
Current: 3.1
During the past 13 years, the highest Debt-to-EBITDA Ratio of Global Bio-chem Technology Group Co was 267.45. The lowest was -53.44. And the median was -3.18.
GBCMY's Debt-to-EBITDA is ranked worse than 63.32% of 1554
companies
in the Consumer Packaged Goods industry
Industry Median: 2.065
vs GBCMY: 3.10
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Global Bio-chem Technology Group Co Debt-to-EBITDA Related Terms
Global Bio-chem Technology Group Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Global Bio-chem Technology Group Co Debt-to-EBITDA Chart
For the Packaged Foods subindustry, Global Bio-chem Technology Group Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Global Bio-chem Technology Group Co Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Global Bio-chem Technology Group Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Global Bio-chem Technology Group Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Global Bio-chem Technology Group Co (GBCMY) has a Debt-to-EBITDA of 1.81 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Global Bio-chem Technology Group Co. According to the industry distribution chart, Global Bio-chem Technology Group Co ranks #984 out of 1554 companies in the Consumer Packaged Goods industry, placing it in the top 63.3%.
Is Global Bio-chem Technology Group Co's Debt-to-EBITDA too high?
Global Bio-chem Technology Group Co's current Debt-to-EBITDA is 1.81. The Consumer Packaged Goods industry median Debt-to-EBITDA is 2.07. Global Bio-chem Technology Group Co's value of 1.81 is 12.3% below this industry median. Based on the distribution chart, Global Bio-chem Technology Group Co ranks #984 out of 1554 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Global Bio-chem Technology Group Co has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Global Bio-chem Technology Group Co's Debt-to-EBITDA compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Global Bio-chem Technology Group Co ranks #984 out of 1554 companies for Debt-to-EBITDA. This places Global Bio-chem Technology Group Co in the lower half of its industry. The industry median Debt-to-EBITDA is 2.07. Global Bio-chem Technology Group Co's value of 1.81 is 12.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.07, based on 1,554 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Global Bio-chem Technology Group Co's current Debt-to-EBITDA of 1.81 is 12.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Global Bio-chem Technology Group Co. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Global Bio-chem Technology Group Co's current Debt-to-EBITDA is 1.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Global Bio-chem Technology Group Co stock overvalued right now?
Global Bio-chem Technology Group Co (GBCMY) has a current Debt-to-EBITDA of 1.81. The current Debt-to-EBITDA is 1.81 and 12.3% below the Consumer Packaged Goods industry median of 2.07. Global Bio-chem Technology Group Co's overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Global Bio-chem Technology Group Co (GBCMY), the current Debt-to-EBITDA is 1.81 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Global Bio-chem Technology Group Co Ltd is engaged in the manufacture and sale of corn refined products and amino acids. The upstream corn refinery serves as a feedstock which breaks down corn kernels into corn starch, gluten meal, fibre and corn oil; and corn starch is further refined through a series of biochemical and/or chemical processes into a wide range of high value-added downstream products. Its segments include the upstream products segment; and the amino acids segment engages in the manufacture and sale of corn based biochemical products, including lysine and threonine. It derives the majority of the revenue from the amino acids segment. Geographically, it operates in The PRC, and Asia, the Americas and other regions.
33GF Score
Get the complete analysis for GBCMY
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GBCMY has been successfully added to your 
